AR083828A1 - Formas cristalinas de un acido alcoxiimidazol-1-ilmetilfenil carboxilico - Google Patents

Formas cristalinas de un acido alcoxiimidazol-1-ilmetilfenil carboxilico

Info

Publication number
AR083828A1
AR083828A1 ARP110104201A ARP110104201A AR083828A1 AR 083828 A1 AR083828 A1 AR 083828A1 AR P110104201 A ARP110104201 A AR P110104201A AR P110104201 A ARP110104201 A AR P110104201A AR 083828 A1 AR083828 A1 AR 083828A1
Authority
AR
Argentina
Prior art keywords
crystalline
ilmetilfenil
alcoxiimidazol
acid
crystalline forms
Prior art date
Application number
ARP110104201A
Other languages
English (en)
Spanish (es)
Inventor
Paul A Fatheree
Venkat Thalladi
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR083828A1 publication Critical patent/AR083828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP110104201A 2010-11-10 2011-11-10 Formas cristalinas de un acido alcoxiimidazol-1-ilmetilfenil carboxilico AR083828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
AR083828A1 true AR083828A1 (es) 2013-03-27

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104201A AR083828A1 (es) 2010-11-10 2011-11-10 Formas cristalinas de un acido alcoxiimidazol-1-ilmetilfenil carboxilico

Country Status (19)

Country Link
US (3) US8362060B2 (enExample)
EP (1) EP2638017B1 (enExample)
JP (2) JP2013542258A (enExample)
KR (1) KR20130130730A (enExample)
CN (1) CN103189362B (enExample)
AR (1) AR083828A1 (enExample)
AU (1) AU2011326622B2 (enExample)
BR (1) BR112013011715A2 (enExample)
CA (1) CA2812598A1 (enExample)
CO (1) CO6741224A2 (enExample)
ES (1) ES2567721T3 (enExample)
IL (1) IL225303A0 (enExample)
MX (1) MX2013005165A (enExample)
NZ (1) NZ609804A (enExample)
PH (1) PH12013500945A1 (enExample)
RU (1) RU2013126403A (enExample)
SG (1) SG189448A1 (enExample)
TW (1) TW201300366A (enExample)
WO (1) WO2012064807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
CN117769540A (zh) * 2021-05-11 2024-03-26 亚士德制药公司 4-[5-[(3S)-3-氨基吡咯烷-l-羰基]-2-[2-氟-4-(2-羟基-2-乙基丙基)苯基]苯基]-2-氟-苯甲腈的盐的固体形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
BR112013011715A2 (pt) 2017-10-31
US8802709B2 (en) 2014-08-12
JP2013542258A (ja) 2013-11-21
CO6741224A2 (es) 2013-08-30
EP2638017A1 (en) 2013-09-18
CN103189362B (zh) 2015-03-11
US8362060B2 (en) 2013-01-29
PH12013500945A1 (en) 2013-07-08
WO2012064807A1 (en) 2012-05-18
CN103189362A (zh) 2013-07-03
HK1187919A1 (zh) 2014-04-17
MX2013005165A (es) 2013-07-05
SG189448A1 (en) 2013-05-31
US20130267573A1 (en) 2013-10-10
KR20130130730A (ko) 2013-12-02
RU2013126403A (ru) 2014-12-20
TW201300366A (zh) 2013-01-01
NZ609804A (en) 2015-02-27
AU2011326622A1 (en) 2013-04-04
ES2567721T3 (es) 2016-04-26
EP2638017B1 (en) 2016-01-27
IL225303A0 (en) 2013-06-27
AU2011326622B2 (en) 2014-12-18
CA2812598A1 (en) 2012-05-18
US20150133518A1 (en) 2015-05-14
JP2016028061A (ja) 2016-02-25
US9249105B2 (en) 2016-02-02
US20120115920A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
PH12013502549B1 (en) Fused benzoxazepinones as ion channel modulators
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
MX338916B (es) Oxazepinas como moduladores del canal de iones.
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MX2013012798A (es) Compuestos heterociclicos fusionados como moduladores del canal de sodio.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
UA111770C2 (uk) Інгібітори бромдомену
AR088018A1 (es) Proceso e intermediarios para preparar lapatinib
IN2015KN00262A (enExample)
MY163394A (en) Substituted aminobutyric derivates as neprilysin inhibitors
MX2012015096A (es) Compuestos heterociclicos fusionados como moduladores del canal ion.
EA201301181A1 (ru) Триазолопиридины
CR20140554A (es) Compuestos de acido dimetil-benzoico
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина
EA201391265A1 (ru) Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
MX2015001374A (es) Compuestos.
MX360048B (es) Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
AR073527A1 (es) Forma cristalina de un acido alcoxiimidazol-1-ilmetil bifenil carboxilico
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids

Legal Events

Date Code Title Description
FB Suspension of granting procedure